Geron Corporation will announce its 2025 financial results on February 25, 2026, followed by a conference call.
Quiver AI Summary
Geron Corporation announced it will release its financial results for the fourth quarter and full year of 2025 on February 25, 2026, before the market opens. This will be followed by a conference call and webcast at 8:00 a.m. Eastern Time, accessible via the company's website. Geron is a biopharmaceutical firm focused on blood cancer treatment, with its telomerase inhibitor RYTELO® (imetelstat) approved for certain adult patients with LR-MDS. The company is also conducting pivotal trials for imetelstat in other blood malignancies, targeting malignant cells by inhibiting telomerase activity. Further information can be found on their website or social media platforms.
Potential Positives
- Geron Corporation is set to announce its fourth quarter and full year 2025 financial results, indicating transparency and shareholder engagement.
- The upcoming conference call and webcast will provide an opportunity for investors to gain insights directly from management.
- RYTELO® (imetelstat) is already approved in the U.S. and EU, highlighting the company's successful advancement of a novel therapy in the market for blood cancer treatment.
- Geron's ongoing pivotal Phase 3 clinical trial for imetelstat demonstrates a commitment to innovation and potential future growth in the hematologic malignancy market.
Potential Negatives
- Announcement of financial results may indicate ongoing financial challenges if the results are anticipated to be poor.
- Geron Corporation is conducting a pivotal Phase 3 clinical trial, which may suggest that their previous product approvals are not sufficient to secure long-term growth without reliance on new clinical data.
FAQ
When will Geron Corporation release its financial results for Q4 and full year 2025?
Geron Corporation will release its financial results on February 25, 2026, before the market opens.
What time is the conference call scheduled for?
The conference call is scheduled for 8:00 a.m. Eastern Time on February 25, 2026.
Where can I find the press release and webcast?
The press release and webcast will be available in the Investors and Media section of Geron's website.
What is RYTELO® used for?
RYTELO® (imetelstat) is approved for treating certain adult patients with LR-MDS and transfusion-dependent anemia.
What is Geron's focus in biopharmaceuticals?
Geron aims to change lives by targeting blood cancers through innovative treatments like telomerase inhibitors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GERN Hedge Fund Activity
We have seen 101 institutional investors add shares of $GERN stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 9,606,217 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,160,517
- NANTAHALA CAPITAL MANAGEMENT, LLC added 9,025,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $12,364,250
- STEMPOINT CAPITAL LP removed 6,649,244 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $9,109,464
- VESTAL POINT CAPITAL, LP removed 6,550,000 shares (-27.5%) from their portfolio in Q3 2025, for an estimated $8,973,500
- MILLENNIUM MANAGEMENT LLC added 5,320,635 shares (+88.0%) to their portfolio in Q3 2025, for an estimated $7,289,269
- EVERSEPT PARTNERS, LP added 5,278,828 shares (+72.1%) to their portfolio in Q3 2025, for an estimated $7,231,994
- GOLDMAN SACHS GROUP INC removed 5,132,997 shares (-24.1%) from their portfolio in Q4 2025, for an estimated $6,775,556
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO
®
(imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit
www.geron.com
or
LinkedIn
.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
[email protected]
